Literature DB >> 29651764

Can functional parameters from hepatobiliary phase of gadoxetate MRI predict clinical outcomes in patients with cirrhosis?

Kumar Sandrasegaran1, Enming Cui2,3, Reem Elkady2,4,5, Pauley Gasparis2, Gitasree Borthakur2, Mark Tann2, Suthat Liangpunsakul6,7.   

Abstract

OBJECTIVES: To determine the value of quantitative parameters of gadoxetate-enhanced magnetic resonance imaging (MRI) in predicting prognosis in patients with cirrhosis.
METHODS: A cohort of 63 cirrhotic patients who had gadoxetate MRI and 2-year clinical follow-up was enrolled. Enhancement ratio (ER), contrast enhancement index (CEI) and contrast enhancement spleen index (CES) were calculated. The usefulness of these parameters and clinical scores, such as Child-Pugh score (CPS) and model for end stage liver disease (MELD), in predicting adverse outcomes, such as variceal bleeding (VB), hepatic encephalopathy (HE) and mortality at 2 years were evaluated.
RESULTS: Fifteen, 31 and 27 patients, respectively, had VB, HE and mortality within 2 years. The ER at 15 min (ER 15) and CES at 20 min (CES 20) were found to be the best MRI predictors. Areas under the receiver operating characteristic curve (AUC) for predicting VB were 0.785, 0.729, 0.673, 0.714, respectively, for ER 15, CES 20, CPS and MELD scores. ER 15 of less than 48 had sensitivity of 96% and specificity of 84% for predicting onset of HE within 2 years.
CONCLUSIONS: In patients with cirrhosis, ER 15 or CES 20 were equivalent or better predictors of major morbidity and mortality compared with commonly used clinical scores. KEY POINTS: • Gadoxetate parameters may identify cirrhotic patients at risk of adverse events. • Gadoxetate parameters usually show superior predictive values compared to clinical scores. • CES 20 score is associated with risk of mortality within 2 years.

Entities:  

Keywords:  Gadolinium; Hepatic encephalopathy; Liver cirrhosis; Magnetic resonance imaging; Patient outcome assessment

Mesh:

Substances:

Year:  2018        PMID: 29651764     DOI: 10.1007/s00330-018-5366-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  54 in total

1.  Comparison of magnetic resonance elastography and gadoxetate disodium-enhanced magnetic resonance imaging for the evaluation of hepatic fibrosis.

Authors:  Ye Ra Choi; Jeong Min Lee; Jeong Hee Yoon; Joon Koo Han; Byung Ihn Choi
Journal:  Invest Radiol       Date:  2013-08       Impact factor: 6.016

Review 2.  Cirrhosis: CT and MR imaging evaluation.

Authors:  Giuseppe Brancatelli; Michael P Federle; Roberta Ambrosini; Roberto Lagalla; Alessandro Carriero; Massimo Midiri; Valérie Vilgrain
Journal:  Eur J Radiol       Date:  2006-12-04       Impact factor: 3.528

3.  Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers.

Authors:  Tsutomu Tamada; Katsuyoshi Ito; Atsushi Higaki; Koji Yoshida; Akihiko Kanki; Tomohiro Sato; Hiroki Higashi; Teruki Sone
Journal:  Eur J Radiol       Date:  2011-02-18       Impact factor: 3.528

Review 4.  Hepatic encephalopathy: how to test and treat.

Authors:  Robert S Rahimi; Don C Rockey
Journal:  Curr Opin Gastroenterol       Date:  2014-05       Impact factor: 3.287

Review 5.  Review article: primary prophylaxis for portal hypertensive bleeding in cirrhosis.

Authors:  J Vlachogiannakos; J Goulis; D Patch; A K Burroughs
Journal:  Aliment Pharmacol Ther       Date:  2000-07       Impact factor: 8.171

6.  Prevalence of minimal hepatic encephalopathy in cirrhotic patients.

Authors:  Héctor Jesús Maldonado-Garza; Genaro Vázquez-Elizondo; Juan Obed Gaytán-Torres; Angel Ricardo Flores-Rendón; Martha Graciela Cárdenas-Sandoval; Francisco Javier Bosques-Padilla
Journal:  Ann Hepatol       Date:  2011-06       Impact factor: 2.400

7.  Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging.

Authors:  Taku Tajima; Hidemasa Takao; Hiroyuki Akai; Shigeru Kiryu; Hiroshi Imamura; Yasushi Watanabe; Jyunichi Shibahara; Norihiro Kokudo; Masaaki Akahane; Kuni Ohtomo
Journal:  J Comput Assist Tomogr       Date:  2010 May-Jun       Impact factor: 1.826

Review 8.  Disaccharides in the treatment of hepatic encephalopathy.

Authors:  Praveen Sharma; Barjesh Chander Sharma
Journal:  Metab Brain Dis       Date:  2013-03-02       Impact factor: 3.584

9.  Separation of advanced from mild hepatic fibrosis by quantification of the hepatobiliary uptake of Gd-EOB-DTPA.

Authors:  Bengt Norén; Mikael Fredrik Forsgren; Olof Dahlqvist Leinhard; Nils Dahlström; Johan Kihlberg; Thobias Romu; Stergios Kechagias; Sven Almer; Örjan Smedby; Peter Lundberg
Journal:  Eur Radiol       Date:  2012-07-27       Impact factor: 5.315

10.  Liver failure after major liver resection: risk assessment by using preoperative Gadoxetic acid-enhanced 3-T MR imaging.

Authors:  Andreas Wibmer; Alexander M Prusa; Richard Nolz; Thomas Gruenberger; Martin Schindl; Ahmed Ba-Ssalamah
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

View more
  6 in total

1.  Advanced liver imaging using MR to predict outcomes in chronic liver disease: a shift from morphology to function liver assessment.

Authors:  Francesco Verde; Valeria Romeo; Simone Maurea
Journal:  Quant Imaging Med Surg       Date:  2020-03

2.  Gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis.

Authors:  Chenxi Liu; Yan Sun; Yao Yang; Yuemin Feng; Xiaoyu Xie; Lingyu Qi; Keke Liu; Ximing Wang; Qiang Zhu; Xinya Zhao
Journal:  Eur Radiol       Date:  2021-02-03       Impact factor: 5.315

3.  Determining the efficacy of functional liver imaging score (FLIS) obtained from gadoxetic acid-enhanced MRI in patients with chronic liver disease and liver cirrhosis: the relationship between Albumin-Bilirubin (ALBI) grade and FLIS.

Authors:  Serdar Aslan; Uluhan Eryuruk; Merve Nur Tasdemir; Ismet Mirac Cakir
Journal:  Abdom Radiol (NY)       Date:  2022-06-07

Review 4.  Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging.

Authors:  Dow-Mu Koh; Ahmed Ba-Ssalamah; Giuseppe Brancatelli; Ghaneh Fananapazir; M Isabel Fiel; Satoshi Goshima; Sheng-Hong Ju; Nikolaos Kartalis; Masatoshi Kudo; Jeong Min Lee; Takamichi Murakami; Max Seidensticker; Claude B Sirlin; Cher Heng Tan; Jin Wang; Jeong Hee Yoon; Mengsu Zeng; Jian Zhou; Bachir Taouli
Journal:  Eur Radiol       Date:  2021-02-01       Impact factor: 5.315

5.  Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases.

Authors:  Lucian Beer; Mattias Mandorfer; Nina Bastati; Sarah Poetter-Lang; Dietmar Tamandl; Dilyana Plamenova Stoyanova; Michael Christoph Elmer; Georg Semmler; Benedikt Simbrunner; Jacqueline C Hodge; Claude B Sirlin; Thomas Reiberger; Ahmed Ba-Ssalamah
Journal:  Eur Radiol       Date:  2019-04-18       Impact factor: 5.315

Review 6.  Quantification of liver function using gadoxetic acid-enhanced MRI.

Authors:  Sarah Poetter-Lang; Nina Bastati; Alina Messner; Antonia Kristic; Alexander Herold; Jacqueline C Hodge; Ahmed Ba-Ssalamah
Journal:  Abdom Radiol (NY)       Date:  2020-10-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.